111
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Anatomical and Functional Results of Early or Late Switching from Anti-VEGF to Dexamethasone Implant in Case of Poor Anatomical Response in Naïve Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

& ORCID Icon
Pages 242-248 | Received 23 Oct 2023, Accepted 21 Jan 2024, Published online: 28 Jan 2024

REFERENCES

  • Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–9. e1. doi:10.1016/j.ophtha.2009.07.017.
  • Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 2010;8(9):1886–94. doi:10.1111/j.1538-7836.2010.03909.x.
  • Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123–62. doi:10.1159/000502041.
  • Adelman RA, Parnes AJ, Bopp S, Saad Othman I, Ducournau D. Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study. Biomed Res Int. 2015;2015:1–8. doi:10.1155/2015/870987.
  • Haller JA, Bandello F, Belfort JR, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–46. e3. doi:10.1016/j.ophtha.2010.03.032.
  • Haller JA, Bandello F, Belfort JR, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology. 2011;118(12):2453–60. doi:10.1016/j.ophtha.2011.05.014.
  • Yeh S, Kim SJ, Ho AC, et al. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology. Ophthalmology. 2015;122(4):769–78. doi:10.1016/j.ophtha.2014.10.013.
  • Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102–12. e1. doi:10.1016/j.ophtha.2010.02.021.
  • Pielen A, Clark WL, Boyer DS, et al. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol. 2017;11:1533–40. doi:10.2147/OPTH.S140665.
  • Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report No. 1. Br J Ophthalmol. 2015;99(7):954–959. doi:10.1136/bjophthalmol-2014-306543.
  • Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA. 2017;317(20):2072–87. doi:10.1001/jama.2017.4568.
  • Korobelnik J-F, Kodjikian L, Delcourt C, et al. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol. 2016;254(12):2307–18. doi:10.1007/s00417-016-3394-y.
  • Bezatis A, Spital G, Höhn F, et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6‐month follow‐up–The SOLO study. Acta Ophthalmol. 2013;91(5):e340–e7. doi:10.1111/aos.12020.
  • Yoon YH, Kim JW, Lee JY, et al. Dexamethasone intravitreal implant for early treatment and retreatment of macular edema related to branch retinal vein occlusion: the multicenter COBALT study. Ophthalmologica. 2018;240(2):81–9. doi:10.1159/000487547.
  • Blanc J, Deschasse C, Kodjikian L, Dot C, Bron A-M, Creuzot-Garcher C. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol. 2018;256(8):1441–8. doi:10.1007/s00417-018-4016-7.
  • Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology. 2012;119(12):2587–91. doi:10.1016/j.ophtha.2012.06.037.
  • Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140(2):. e256. 1–. e. 7. doi:10.1016/j.ajo.2005.03.003.
  • Feltgen N, Hattenbach LO, Bertelmann T, et al. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1‐year results of the COMRADE extension study. Acta Ophthalmol. 2018;96(8):e933–e41. doi:10.1111/aos.13770.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.